


Figure 1. Algorithm for investigations and management in PIMS/MIS-C



*As per institutional policy for KD

**High risk criteria for Kawasaki Disease: Kawasaki disease shock syndrome, macrophage activation syndrome, fever ≥ 10 days, age ≤ 1, and coronary artery abnormalities on baseline echocardiogram

***Anakinra, tocilizumab or infliximab may be considered in consultation with pediatric rheumatology

ASA acetylsalicylic acid, CSS cytokine storm syndrome, KD Kawasaki disease, IVIg intravenous immunoglobulin, MAS macrophage activation syndrome

© Canadian Paediatric Society

Source: Spring 2021 Update – Paediatric inflammatory multisystem syndrome temporally associated with COVID-19, Acute Care Committee, May 3, 2021. Available at www.cps.ca